Maintaining Skeletal Health in Postmenopausal Women With Surgically Resected Stage I-IIIa Hormone-Receptor Positive Breast Cancer Who Are Receiving Anastrozole, Through the Use of Alendronate as Determined by the Osteoporosis Australia Bone Maintenance Algorithm.

Trial Profile

Maintaining Skeletal Health in Postmenopausal Women With Surgically Resected Stage I-IIIa Hormone-Receptor Positive Breast Cancer Who Are Receiving Anastrozole, Through the Use of Alendronate as Determined by the Osteoporosis Australia Bone Maintenance Algorithm.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms BATMAN
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12605000003673).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top